The “FDA approval defense”: penetrating the protective shield
نویسندگان
چکیده
منابع مشابه
The "FDA approval defense": penetrating the protective shield.
Pharmaceutical manufacturers decry the purported burdens imposed by Federal regulation when it suits their proprietary interests, yet they sing a wholly different tune when defending product liability suits. As product liability defendants, they unabashedly seek the protective womb of Food and Drug Administration (FDA) regulation, arguing that agency approval of their drug and its labeling prec...
متن کاملFDA drug approval summaries: fulvestrant.
Patients with hormone-sensitive breast cancer who have responded to tamoxifen may receive additional benefit from a second endocrine agent following progression or relapse after tamoxifen therapy. Fulvestrant (Faslodex((R)), ICI 182780, AstraZeneca Pharmaceuticals; Wilmington, Delaware) is a selective antagonist of estrogen designed to have no estrogenic effects. Lack of aqueous solubility led ...
متن کاملFDA drug approval summaries: oxaliplatin.
The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references. A single, multicenter, randomized trial, enrolling 463 patients with metastatic colorectal carcinoma whose disease had recurred o...
متن کاملSailing the straits of approval: the nature of FDA approval and its implications for surgeons.
Use of Food and Drug Administration-approved medications and products for other than the approved indications is common in facial plastic surgery and violates no laws. Addressing practical concerns about such use strengthens the doctor-patient relationship and can minimize the risk of successful allegations of negligence in the event of untoward outcomes. The facial plastic surgeon can find sup...
متن کاملFDA Approval Summary: Ramucirumab for Gastric Cancer.
The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma initially as monotherapy (April 21, 2014) and subsequently as combination therapy with paclitaxel (November 5, 2014). In the monotherapy trial, 355 patients in the indicated population were randomly allocated (2:1) to recei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Risk and Safety in Medicine
سال: 1994
ISSN: 0924-6479
DOI: 10.3233/jrs-1994-4301